|
|
|
| Correlation between serum carnitine and sarcopenia and nutrition status in colorectal cancer patients undergoing radiotherapy |
| Yue Yaling ,Jiang Liqiang, Tian Sui, Liu Zheng |
| The Third Department of Oncology Handan Central Hospital Handan 056001 Hebei China |
|
|
|
|
Abstract Objective To investigate the correlation between serum carnitine levels and sarcopenia and nutritional status in colorectal
cancer patients undergoing radiotherapy. Method A total of 84 patients with colorectal cancer radiotherapy who were treated in our hospital
from January 2020 to December 2021 were selected as the case group including 42 cases with serum carnitine level ≥39. 77 μmol/ L high
level group and serum carnitine level was lower than 39. 77 μmol / L are 42 cases low level group . and 61 cases of healthy subjects
during the same period were selected as the control group. Serum free carnitine levels were determined by enzyme cycle method and
serum free carnitine levels in the case group and control group were analyzed. The nutritional status and muscle status of the two groups
in the case group were analyzed Pearson correlation was used to analyze the correlation between serum carnitine levels and sarcopenia
and nutritional status in colorectal cancer radiotherapy patients. Result The serum free carnitine level in the case group was
significantly lower than that in the control group P<0. 05 . In the case group the serum carnitine levels walking speed hand grip
strength prealbumin femoral neck BMD hemoglobin Hb albumin ALB total protein TP skeletal muscle index SMI and
lean body tissue index LTI were significantly different P<0. 05 Pearson correlation analysis showed that serum carnitine levels
were significantly associated with SMI r = 0. 676 femoral neck BMD r = 0. 544 walking speed r = 0. 560 hand grip strength
r = 0. 609 LTI r = 0. 411 TP r = 0. 532 prealbumin r = 0. 532 ALB r = 0. 623 and Hb r = 0. 376 were positively
correlated P<0. 05 . Conclusion The serum carnitine level is highly expressed in patients with colorectal cancer radiotherapy which
can be used as a serum marker for sarcopenia and nutritional status in patients with colorectal cancer radiotherapy.
|
|
Received: 15 March 2022
|
|
|
|
|
|
|
